LSE:DNL (Diurnal Group Plc)

Diurnal is an innovative pharmaceutical company that creates high-value therapeutics using advanced proprietary formulations and novel physiological treatment regimes of approved drugs for use in the endocrine (hormone) area. Founded in 2004, Diurnal is headquartered in Cardiff, United Kingdom, and is a specialty pharma company developing hormone therapeutics for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency, and hypogonadism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.